Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel

Livnat Brill, Esther Ganelin-Cohen, Ron Dabby, Shira Rabinowicz, Efrat Zohar-Dayan, Netaniel Rein, Eyal Aloni, Yuval Karmon, Adi Vaknin-Dembinsky*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Introduction: Myelin oligodendrocyte glycoprotein (MOG) antibody associated disorders (MOGAD) have been recognized over the past 10 years as distinct inflammatory, demyelinating diseases of the central nervous system (CNS). Antibodies against MOG are found mostly in patients with optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and aquaporin-4 antibody (AQP4-abs)-seronegative neuromyelitis optica spectrum disorders (NMOSD). However, data on the disease course and disability outcomes of these patients are scarce. Aim: To describe clinical and paraclinical features associated with MOG antibodies (abs) in a cohort of patients in Israel, and to assess baseline prognostic features of MOG-ab-associated diseases after a first acute demyelinating event. Methods: MOG-abs were identified in serum using a cell-based assay, and clinical data were collected from the patients' medical records. Results: Of 683 patients with demyelinating diseases tested for MOG-abs, 53 were positive (7.7%), with ON the most common presenting phenotype (68%). The age range of MOG-abs seropositive patients was 1–66 years, with increased prevalence in children (19% compared to 6.7% in adults) (p < 0.01). The highest prevalence of seropositivity was observed in children aged younger than 10 years (25.5%), followed by those aged 31–40 years (16.6%). Conclusions: MOGAD are distinct autoimmune diseases that occurs at all stages of life with a significantly higher prevalence in children; the main clinical presenting phenotype in the entire cohort is ON and young children most often presented with ON or ADEM. Our data highlight the need for repeated evaluation of MOG-abs in patients with acquired CNS demyelinating disorders, especially in children under 10 and adults between 31 and 40 years of age.

Original languageEnglish
Article number612304
JournalFrontiers in Neurology
StatePublished - 21 Jan 2021


  • ADEM
  • MOG antibody disease (MOGAD)
  • MOG-IgG
  • MS
  • demyelinating diseases
  • encephalitis
  • optic neuritis (ON)


Dive into the research topics of 'Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel'. Together they form a unique fingerprint.

Cite this